Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota.
Hosomi K, Saito M, Park J, Murakami H, Shibata N, Ando M, Nagatake T, Konishi K, Ohno H, Tanisawa K, Mohsen A, Chen YA, Kawashima H, Natsume-Kitatani Y, Oka Y, Shimizu H, Furuta M, Tojima Y, Sawane K, Saika A, Kondo S, Yonejima Y, Takeyama H, Matsutani A, Mizuguchi K, Miyachi M, Kunisawa J. · 2022
Read Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota. by Hosomi K, Saito M, Park J, Murakami H, Shibata N, Ando M, Nagatake T, Konishi K, Ohno H, Tanisawa K, Mohsen A, Chen YA, Kawashima H, Natsume-Kitatani Y, Oka Y, Shimizu H, Furuta M, Tojima Y, Sawane K, Saika A, Kondo S, Yonejima Y, Takeyama H, Matsutani A, Mizuguchi K, Miyachi M, Kunisawa J. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9388534.txt.
Introduction
Hosomi and co-authors test a gut bacterium, Blautia wexlerae, against obesity and type 2 diabetes. A survey of Japanese adults first flagged the genus as scarce in people with those conditions. The team then fed the bacterium to mice on a high-fat diet. Metabolic and immune readouts were tracked in both settings.
Treated mice gained less weight and showed better diabetes markers. The bacterium makes unusual products, including S-adenosylmethionine, acetylcholine, and l-ornithine. Its sugar handling stores amylopectin and yields succinate, lactate, and acetate. Gut community makeup shifted along with the host changes. Inflammation eased in treated animals. The authors suggest this microbe, common in Japanese gut profiles, as a preventive or treatment candidate. Human trials would be the next test.
Catalog record
| CREATOR | Hosomi K, Saito M, Park J, Murakami H, Shibata N, Ando M, Nagatake T, Konishi K, Ohno H, Tanisawa K, Mohsen A, Chen YA, Kawashima H, Natsume-Kitatani Y, Oka Y, Shimizu H, Furuta M, Tojima Y, Sawane K, Saika A, Kondo S, Yonejima Y, Takeyama H, Matsutani A, Mizuguchi K, Miyachi M, Kunisawa J. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 96 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota By Koji Hosomi, Mayu Saito, Jonguk Park, Haruka Murakami, Naoko Shibata, Masahiro Ando, Takahiro Nagatake, Kana Konishi, Harumi Ohno, Kumpei Tanisawa, Attayeb Mohsen, Yi-An Chen Published in: Nature Communications DOI: 10.1038/s41467-022-32015-7 ABSTRACT The gut microbiome is an important determinant in various diseases. Here we perform a cross-sectional study of Japanese adults and identify the Blautia genus, especially B. wexlerae, as a commensal bacterium that is inversely correlated with obesity and type 2 diabetes mellitus. Oral administration of B. wexlerae to mice induce metabolic changes and anti-inflammatory effects that decrease both high-fat diet–induced obesity and diabetes. The beneficial effects of B. wexlerae are correlated with unique amino-acid metabolism to produce S-adenosylmethionine, acetylcholine, and l-ornithine and carbohydrate metabolism resulting in the accumulation of amylopectin and production of succinate, lactate, and acetate, with simultaneous modification of the gut bacterial composition. These findings reveal unique regulatory pathways of host and microbial metabolism that may provide novel strategies in preventive and therapeutic approaches for metabolic disorders. INTRODUCTION Because of its rising prevalence and associated comorbidities such as type 2 diabetes mellitus (T2DM), obesity is a major public-health concern1. T2DM, which is caused by genetic background, overnutrition, and other environmental factors, is a global epidemic disease that is characterized by inflammation, metabolic disorders such as insulin resistance, and β-cell dysfunction2. The gut microbiota is recognized as a key environmental factor that contributes to the pathophysiology of obesity3–5 and T2DM6–8. For example, the gut microbiota produces a wide range of metabolites, some of which—such as lipopolysaccharide and tryptophan-derived metabolites—appear to be causative disease factors9–11. In contrast to the gut microbiota’s disease-promoting effects, the short-chain fatty acids (SCFAs) and secondary bile acids generated by microbes are known to have anti-obesity and anti-diabetes properties12–15. Consistent with the pivotal role of the gut microbiota in the control of adipose tissue, obese persons and patients with T2DM have an altered gut microbial composition16. For example, diabetic European women demonstrate alterations in the composition and function of the gut microbiota7. Of note, the mathematical model established from their metagenomic profiles identified T2DM with high accuracy among Europeans—but not Chinese people—indicating that the discriminant metagenomic markers for T2DM differ between European and Chinese populations7. Several lines of evidence have indicated regional differences in gut microbial composition17,18, which are influenced by various environmental factors including diet19–21 and genetic background5,22. However, the mechanisms underlying the effects of differences in gut microbial composition on obesity and T2DM remain poorly understood. Japanese people have a unique dietary culture and habits, and their gut microbiome shows greater abundance in the genera Bifidobacterium and Blautia compared with those of people in other countries18. Several studies have investigated the gut microbiota of Japanese subjects and its association with obesity and T2DM. For example, one group23 used 16S rRNA amplicon sequencing to analyze 10 subjects (4 non-obese and 6 obese), and others24,25 applied a reverse transcription-quantitative PCR method to evaluate Japanese patients with T2DM (50 or 19 subjects). In addition to their unique gut microbial composition, Japanese people exhibit the highest average life span worldwide and a very low body mass index (BMI)26; therefore a study involving Japanese participants may increase our understanding of the gut microbiota and its contributions to ameliorating obesity and T2DM. In this work, we conducted a cross-sectional study of Japanese adults and found that the abundance of Blautia wexlerae was inversely correlated with obesity and T2DM. In addition, the administration of B. wexlerae causatively decreased high-fat diet-induced obesity and diabetes in mice. Furthermore, we identified several unique metabolites of B. wexlerae that altered energy metabolism, exerted anti-inflammatory effects, and changed the composition of the gut bacterial environment. RESULTS Japanese cohort study We conducted a cross-sectional study involving 217 participants as a discovery cohort to assess the association between the gut microbiota and obesity or T2DM in Japanese adults (Supplementary Table 1, 2). Multiple-regression analysis revealed high correlation between the gut microbiota and BMI (R2 = 0.32) and T2DM (R2 = 0.29). Multiple-regression analysis to explore gut microbiome alterations in obesity identified 16 genera that were related to BMI (Supplementary Table 3), among which 11 organisms were selected according to the R-squared score from single regression analysis (Fig. 1A). In the same way, combining multiple logistic regression analysis and single logistic regression analysis found 8 organisms that were differentially abundant in samples from T2DM patients compared with control subjects (Fig. 1B, Supplementary Table 4). Obesity (BMI ≥ 25 in accordance with the guideline of the Japan Society for the Study of Obesity27) and T2DM were commonly associated with decreased abundance of Blautia, Faecalibacterium, and Butyricicoccus and an increase in Megasphaera abundance (Fig. 1C, Supplementary Fig. 1A, B). Faecalibacterium and Butyricicoccus are known butyrate-producing bacteria16,28, and previous studies showed potential beneficial roles of Faecalibacterium in both human cohorts and animal models16.Fig. 1Intestinal bacterial genera associated with body mass index (BMI) and type 2 diabetes mellitus (T2DM) in Japanese adults.A BMI-related bacterial genera, which were selected and ranked according to R2 score from single regression analysis (P < 0.05) among 16 genera that were identified through multiple-regression analysis by forward selection (Supplementary Table 3) by using the data of the 217 participants (Supplementary Table 1). B T2DM-related bacterial genera, which are selected and ranked according to R2 score from single regression analysis (P < 0.05) among 22 genera that were identified through multiple logistic regression analysis by forward selection (Supplementary Table 4) by using the data of 192 participants (comprising 147 nonDM subjects and 45 T2DM patients and excluding 25 patients with Type 1 diabetes) (Supplementary Table 1). C Intestinal genera associated with both BMI and T2DM. D Odds ratios for Blautia abundance in the development of obesity (BMI ≥ 25) and T2DM. E Estimation of Blautia species according to BlastN analysis of representative OTU sequences. Although several studies have implicated the involvement of Blautia in the development of obesity and T2DM16,29, little definitive information is available. We therefore assessed the effect of Blautia on obesity and T2DM via evaluating the odds ratio (OR) and learned that the Blautia abundance was inversely correlated to the ORs of obesity and T2DM (Fig. 1D, Supplementary Table 5 and 6). This finding was supported by quantitative PCR data, which showed a similar tendency regarding the relative abundance of Blautia according to 16S rRNA gene amplicon sequencing analysis (Supplementary Fig. 2A–C). Notably, because Blautia was highly discriminant for obesity and T2DM in our Japanese population, we subsequently focused this study on the role of Blautia in the control of obesity and diabetes. We next investigated whether factors other than the prevalent obesity and T2DM, such as age, sex, and medication (e.g., metformin), influenced the proportion of Blautia30 but found no association between Blautia abundance and these factors (Supplementary Fig. 3). Furthermore, we tested the gut microbiome composition in nonDM and T2DM samples by using data sets randomly selected from study participants that were similarly distributed in terms of age and sex. Blautia abundance was significantly increased in the adjusted nonDM samples compared with T2DM samples (Supplementary Table 7), suggesting little confounding effect of factors such as age and sex on this analysis. To confirm the